This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BXRX Baudax Bio (BXRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Baudax Bio Stock (NASDAQ:BXRX) 30 days 90 days 365 days Advanced Chart Get Baudax Bio alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0352-Week Range$0.01▼$3.47Volume310,872 shsAverage Volume281,029 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Read More… Receive BXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BXRX Stock News HeadlinesBaudax Bio Announces Corporate UpdateOctober 18, 2023 | finance.yahoo.comBaudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug TagOctober 2, 2023 | msn.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 29, 2025 | Paradigm Press (Ad)Why Is Baudax Bio (BXRX) Stock Up 75% Today?September 28, 2023 | investorplace.comBaudax Bio Shares Double After Orphan Drug Designation for TI-168September 28, 2023 | marketwatch.comBaudax Bio: FDA Grants Orphan Drug Designation To TI-168 For Hemophilia A With InhibitorsSeptember 28, 2023 | markets.businessinsider.comHere's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock NowSeptember 18, 2023 | finance.yahoo.comBaudax Bio to Participate in the H.C. Wainwright Global Investment ConferenceSeptember 7, 2023 | finance.yahoo.comSee More Headlines BXRX Stock Analysis - Frequently Asked Questions How were Baudax Bio's earnings last quarter? Baudax Bio, Inc. (NASDAQ:BXRX) issued its earnings results on Wednesday, August, 16th. The company reported ($1.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.04) by $0.55. When did Baudax Bio's stock split? Shares of Baudax Bio reverse split on Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Baudax Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Baudax Bio investors own include Vanguard Dividend Appreciation ETF (VIG), Vanguard Total Stock Market ETF (VTI), iShares Russell 1000 Growth ETF (IWF), Schlumberger (SLB), ARK Innovation ETF (ARKK), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/16/2023Today4/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BXRX CIK1780097 Webwww.baudaxbio.com Phone484-395-2440Fax484-395-2471Employees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,790,000.00 Net MarginsN/A Pretax Margin-18,950.64% Return on EquityN/A Return on Assets-175.11% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.27 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($14.93) per share Price / Book0.00Miscellaneous Outstanding Shares52,460,000Free Float52,408,000Market Cap$1.14 million OptionableNot Optionable Beta1.57 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:BXRX) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baudax Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baudax Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.